US · Healthcare · Biotechnology
EPS came in at -0.45 against a street estimate of -0.33 — a miss of 36.4%.
Analysts rate CalciMedica, Inc. Common Stock a strong buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $38.00.
| Fund | Stake |
|---|---|
| Woodline Partners LP | 7.29% |
| Heights Capital Management Inc | 4.56% |
| StemPoint Capital LP | 3.65% |
| Squadron Capital Management LLC | 3.65% |
| Stonepine Capital Management Llc | 1.82% |
| L1 Global Manager Pty Ltd | 0.73% |
| Morgan Stanley - Brokerage Accounts | 0.42% |
| CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 0.35% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CalciMedica, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.